If you're taking, or considering, semaglutide or tirzepatide for weight management, you may have come across recent headlines suggesting these medications can affect bone density. Bone health is a reasonable thing to think about during any period of substantial weight loss, and research published in 2026 has given clinicians and patients more specific information to work with, rather than leaving the question to speculation.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation from a licensed clinician who knows your health history.
Why bone health comes up in conversations about GLP-1 medications
Semaglutide and tirzepatide can lead to substantial weight loss, and clinicians have long known that significant weight loss from any cause tends to come with some reduction in bone mineral density. That relationship isn't new or unique to GLP-1 medications: it has been studied for years in people who lose weight through diet and exercise or bariatric surgery. What's newer is research looking specifically at whether semaglutide and tirzepatide follow the same pattern, and whether there's anything distinct about how these particular medications interact with bone.
Bone health also matters simply because of who tends to use these medications. Many adults being treated for obesity or type 2 diabetes are already at an age, or have other risk factors, where bone density is worth paying attention to regardless of any medication they take.
How weight loss affects bone, regardless of the method
Bone is living tissue that responds to the forces placed on it. Mechanical loading, the pressure and pull created by body weight and muscle activity, is one of the signals that tells bone to stay dense and continue rebuilding itself. When a person loses a substantial amount of weight, that mechanical loading decreases, and some corresponding decline in bone mineral density has been observed across many different weight-loss methods, not just medication.
This is part of why clinicians who care for patients after bariatric surgery already monitor bone health as a standard part of follow-up. It's a known consequence of significant weight loss in general, and it's the backdrop against which newer GLP-1 research needs to be understood, rather than an entirely separate concern.
What a 2026 study found about semaglutide, tirzepatide, and hip bone density
A retrospective study published in 2026 in the Journal of Clinical Endocrinology and Metabolism, led by researchers at Weill Cornell Medical College and the Hospital for Special Surgery, looked at this question directly. The researchers identified 255 adults who had used semaglutide or tirzepatide for at least six months and had bone density (DXA) scans both before starting treatment and afterward. Each person was matched, by age, sex, body mass index, and diabetes status, to a similar adult who wasn't using either medication and who also had DXA scans over a comparable period.
Over a median follow-up of about 17 months, the group using semaglutide or tirzepatide lost a median of roughly 5% of their body weight. Both groups, medication users and matched non-users alike, showed measurable declines in bone mineral density at the total hip and femoral neck over the study period. The notable difference emerged once the researchers separated participants by whether or not they had type 2 diabetes.
| Group | Semaglutide/tirzepatide users | Matched non-users |
|---|---|---|
| Without type 2 diabetes | About −1% per year | About −0.6% per year |
| With type 2 diabetes | Bone loss was similar between medication users and non-users | |
Why diabetes status appeared to matter in the findings
Among participants without type 2 diabetes, those using semaglutide or tirzepatide lost hip bone density at a somewhat greater annualized rate than their matched non-users. Among participants with type 2 diabetes, hip bone loss was similar between medication users and non-users. Within the medication group overall, the researchers also found that greater weight loss correlated with greater bone loss at the hip and femoral neck, a pattern they pointed to as evidence that weight loss itself, rather than a separate direct effect of the drug on bone, appears to explain much of what was observed.
The study's authors concluded that the effect of GLP-1 receptor agonists on bone may differ by diabetes status, with weight loss driving bone loss mainly in people who don't have diabetes. That's a meaningfully different message than a blanket claim that "GLP-1 medications damage your bones," and it's worth keeping the nuance rather than flattening it.
What this does, and doesn't, tell us about fracture risk
A decline in bone mineral density is a recognized risk factor for fracture, but it isn't the same thing as a fracture, and this study didn't track fracture outcomes directly. Fracture risk depends on several factors beyond bone density alone, including muscle strength, balance, fall risk, and overall nutrition. The study's authors were explicit that more research is needed to understand how these bone density changes translate into real-world fracture risk over time, particularly since the study followed a single center's patients over a relatively short period.
It's also worth remembering that both groups in the study, including the adults who weren't using GLP-1 medications, showed some bone loss. That tells us part of what's being observed reflects the general relationship between weight loss and bone remodeling described earlier in this article, not something entirely unique to semaglutide or tirzepatide. You can read more about how weight loss on these medications affects the body more broadly in our guide to preserving muscle mass during GLP-1 treatment.
Supportive habits for bone health during treatment
Your clinician directs your individual treatment plan, but a few general habits often come up in conversations about protecting bone and muscle during significant weight loss:
- Weight-bearing and resistance exercise, such as walking, strength training, or bodyweight exercises, which provide the mechanical loading that supports bone density.
- Adequate protein intake, which supports both muscle and bone tissue during a period of overall calorie reduction.
- Adequate calcium and vitamin D intake, from food or, if your clinician recommends it, a supplement.
- Avoiding smoking and limiting alcohol, both of which are independently associated with lower bone density.
- Keeping up with any bone density screening your clinician recommends, particularly if you already have risk factors for reduced bone density.
None of these habits guarantee that bone density will be preserved, and they aren't a substitute for your prescribed treatment plan. They're general considerations to raise with your own clinician, who can weigh them against your individual health history.
Who should flag bone health history before starting treatment
People with an existing diagnosis of osteoporosis or osteopenia, a personal history of a fragility fracture (a fracture from a fall from standing height or lower), a family history of osteoporosis, long-term steroid use, early menopause, or other recognized risk factors for reduced bone density should mention this history to the clinician evaluating them for GLP-1 treatment. This history doesn't automatically rule treatment out, but it can help your clinician decide whether a baseline DXA scan or ongoing bone-health monitoring makes sense as part of an individualized plan. Our guide on testosterone therapy and bone health walks through how a DXA scan and its results are generally interpreted, if you'd like more detail on that process.
If you're already managing another condition that affects bone, such as chronic kidney disease, it's also worth reviewing that alongside your clinician; our article on GLP-1 medications and kidney health covers a related set of monitoring questions.
The bottom line
Bone density decline appears to accompany significant weight loss in general, and a 2026 study suggests semaglutide and tirzepatide use may add to that effect specifically in adults without diabetes, tracking with how much weight is lost. This isn't, on its own, a reason for most people to avoid these medications, but it's a reasonable topic to raise with your prescribing clinician, particularly if you already have risk factors for reduced bone density. If you experience side effects at any point during treatment, our overview of side effects of GLP-1 medications is a good next read.
You can find more articles like this one in our Weight Management section.
Important Safety Information
Indication. Semaglutide is FDA-approved as Ozempic® for type 2 diabetes and as Wegovy® for chronic weight management; tirzepatide is FDA-approved as Mounjaro® for type 2 diabetes and as Zepbound™ for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity, each used alongside a reduced-calorie diet and increased physical activity as appropriate to the approved use. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate.
Common side effects. The most commonly reported side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. These are often mild and tend to ease over time, particularly as the dose is increased gradually.
Warnings. These medications carry a boxed warning regarding thyroid C-cell tumors seen in rodent studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Tell your provider about any history of osteoporosis or fragility fracture, pancreatitis, gallbladder disease, kidney disease, diabetic retinopathy, or if you are pregnant, planning to become pregnant, or breastfeeding.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Do GLP-1 medications cause bone loss?
Weight loss itself, whether from diet, bariatric surgery, or a GLP-1 medication, reduces the mechanical loading on bone and is a recognized contributor to bone mineral density decline. A 2026 study found that adults without type 2 diabetes who used semaglutide or tirzepatide lost hip bone density at a somewhat greater rate than matched non-users, while adults with type 2 diabetes showed similar bone loss whether or not they used the medication.
Does this mean semaglutide or tirzepatide causes osteoporosis?
No. The study measured a difference in the rate of bone density decline over time, not a diagnosis of osteoporosis, and it did not track whether participants went on to have fractures. Bone density is one of several factors that determine fracture risk, alongside muscle strength, balance, and nutrition, and researchers have said more study is needed to understand how these findings translate into real-world fracture risk.
Why did diabetes status seem to matter in the research?
In the study, greater hip bone loss in the medication group compared to matched non-users showed up specifically among participants without type 2 diabetes, while bone loss was similar between the two groups among participants with type 2 diabetes. The researchers also found that within the medication group, more weight loss was associated with more bone loss, suggesting the amount of weight lost plays a meaningful role.
Should I get a bone density scan before starting a GLP-1 medication?
Not automatically. A baseline DXA bone density scan is more often considered for people who already have risk factors for reduced bone density, such as a personal or family history of osteoporosis, a prior fragility fracture, long-term steroid use, or early menopause. Whether a scan makes sense for you is a decision to make with your prescribing clinician based on your individual history.
What can I do to protect my bones while losing weight on a GLP-1 medication?
Weight-bearing and resistance exercise, adequate protein intake, and adequate calcium and vitamin D intake are commonly discussed supportive habits during significant weight loss. These habits don't guarantee bone density will be preserved, and they aren't a substitute for your prescribed treatment plan, but they're reasonable topics to raise with your own clinician.
Does this research apply to compounded semaglutide or tirzepatide too?
The study looked at semaglutide and tirzepatide as active medications and did not separately analyze brand-name products versus compounded formulations of the same molecules. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate.
